Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tomorrow mid 0.01 ... Friday breaks 0.02
A logic close will be between .012 - .014
0.006-007 here we go !
Close .006 please
All that to hit ONE penny !!!
That thing wants to Explode !
2 million shares and buying more
03-05 very soon
Need to break the 003
WTF
BioCorRx Inc. Unveils New UnCraveRx™ Weight Loss Program; Appoints Notable Dr. Kenneth Orbeck as Medical Director
May 01, 2019 08:30 ET | Source: BioCorRx Inc
ANAHEIM, CA, May 01, 2019 (GLOBE NEWSWIRE) -- ?via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that it has unveiled its new UnCraveRx™ Weight Loss Program and appointed Dr. Kenneth Orbeck as Medical Director. UnCraveRx™ is a novel weight loss program that combines medically assisted weight loss management with lifestyle behavioral support.
The UnCraveRx™ specialized weight loss program is expected to launch on October 1, 2019.The goal of the program is to help participants achieve healthy, sustainable weight goals. UnCraveRx™ will combine a naltrexone pellet insertion procedure performed by a licensed medical professional. Naltrexone can reduce food cravings as reported by individuals who took part in several pilot weight loss programs. The second part of the program is a lifestyle behavioral therapy and nutritional coaching. Program participants will immediately begin working with a coach to develop a roadmap for success.
Dr. Kenneth Orbeck owns and operates an integrative and functional medical center in South Carolina. His practice is based in bio identical hormone therapy; BodyLogicMD of Greenville and Greenville Rejuvenation, Dr. Orbeck dedicates his practice to helping women and men find relief from hormonal imbalances such as menopause, andropause (the male menopause), adrenal fatigue and thyroid disorders by using a personal functional approach to wellness, combining customized nutrition and fitness regimens with bio identical hormone therapy. Dr. Orbeck believes that proper diet, regular exercise and balanced hormones are the cornerstones of longevity. Dr. Orbeck examines the interaction between a person's genetic, environmental, and lifestyle factors for an individualized treatment plan on each patient. Dr. Orbeck utilizes advanced hormonal application through subcutaneous pellet therapy and is a national speaker on advanced hormone and pellet therapy. Dr. Kenneth Orbeck received his undergraduate degree from Calvin College in 1983 and completed his Doctorate in Osteopathic Medicine at the University of Osteopathic Medicine and Health Sciences in 1987, where he served as student chairman for the American College of General Practitioners. Before practicing medicine, Dr. Orbeck fulfilled his post graduate training at Mt. Clemens General Hospital in 1988. Dr. Orbeck is a fellow in Anti-aging, Regenerative Medicine (FAAFM), and is certified by the American board of Anti-aging and Regenerative Medicine (ABAARM).
Dr. Kenneth Orbeck stated, “As a physician working in integrative and functional medicine, I encounter individuals who are seeking optimal health. One of the greatest challenges and concerns of many patients is regarding their weight. Weight abnormalities are complex and require a comprehensive approach to achieve recovery and optimal metabolic health. Although many factors are involved in weight management, caloric intake must be addressed regarding a person's addiction to food or “need to feed.” Psychological issues play a very important role in oversized individuals as well. In the forefront of addiction medicine is the use of naltrexone, a proven treatment regimen that can curtail the severe cravings often encountered by victims of addiction. Although naltrexone has been proven highly effective, current application methods lack the desired consistent serum levels needed to avoid unnecessary side effects. Cutting edge developments have allowed the use of naltrexone to be inserted through subcutaneous application which ensures constant drug delivery and controlled serum levels avoiding the unnecessary side effects. This exciting development has shown great promise in addiction medicine including weight management. I am very enthusiastic about the potential benefits that can now be offered to individuals suffering from weight and addiction issues.”
Lourdes Felix, CFO, COO and Director, stated, “We are proud to announce launch of our new weight loss program and the addition of Dr. Kenneth Orbeck as Medical Director. We believe Dr. Orbeck will be invaluable to the program and will be instrumental in fulfilling UnCraveRx’s objective to help individuals who have struggled to maintain their weight loss over time, and to help those who would benefit from losing weight and building on their progress. Research has shown, individuals that struggle with excess weight are dealing with multifaceted circumstances of biological, genetic and behavioral factors. Our approach is unique and will be able to address the complexities of losing weight and helping individuals optimize their health and wellness.”
Up 29% so far today !
Lol Funny !!
Some good buys are happening right now !!!!!
Investors Regaining confidence in the stock !!! BICX ......$5 PPS
$15 per share !!! WOOOOW :)
BioCorRx Announces Above Market $6 Million Private Placement at $15 Per Share
April 02, 2019 07:30 ET | Source: BioCorRx Inc
ANAHEIM, CA, April 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced the Company completed a private placement, whereby it issued 400,000 common stock shares at a price of $15.00 per share, for total proceeds of $6 million. The $15.00 price paid by two investors, one of whom is Louis Lucido, a Director, represents a 282% premium to the market price of $3.93 per share, as of the market close on April 1, 2019.
A portion of the capital will be used to fund the launch and expansion of the Company’s weight loss program in the upcoming months and to further its product development pipeline in the addiction treatment field.
The investors will also receive royalties from each future sale of the Company’s weight loss program. A total of $37.50 out of the gross sales amount of each program sold will be paid to the investors starting on the date the first program is sold and ending on the 3rd anniversary of the initial sales date; and a total of $25.00 out of the gross sales amount of each program sold will be paid to the investors thereafter, ending on the 15th anniversary of the initial sales date.
Lourdes Felix, CFO, COO and Director, stated, “We are extremely pleased with the terms of this funding, and appreciative of the support from these investors who conducted extensive due diligence prior to this transaction. We believe the significant investment premium over our current share price is further validation of our business strategy, product pipeline, and the growth opportunities ahead. This funding advances our goal to list on a national exchange. We have made tremendous progress this year and we believe this private placement funding, coupled with the recent NIDA grant award of nearly $5.7 million for BICX102, will allow us to accelerate our product development and growth strategy and create significant value for our shareholders.”
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance abuse addiction and related disorders. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, and can prevent opioid overdose following relapse. The second component of the program developed by BioCorRx Inc. is a Cognitive Behavioral Therapy (CBT) program tailored specifically for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and its product pipeline, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
Media Relations Contact:
Kyle Porter
CMW Media
kyle@cmwmedia.com
(858) 264-6600
Form S-1 ? Post a link please
Well !! The trading volume now is very low compared to the before . But the value is much higher .
So far , $33,700 traded today .
That's A LOT of buying !!!!!!
Agree !
121K buy just went through .
Bid squeezing the ask !! Get ready
Will breakout any second !!!!
Look for 0.20+ short term after grant news !!!
Drug Addiction Market Pipeline Therapeutics H1, 2018 Product Description, Mechanism of Action and Methodology
June 14, 2018
Drug Addiction market Pipeline Review, H1 2018 report delivers the Drug Addiction latest Pharmaceutical and Healthcare disease pipeline guide, therapeutics under complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The Drug Addiction industry also report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news.
Drug Addiction Market pipeline report also reviews of key players involved in therapeutic development for Drug Addiction Market and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery.
Browse More Detail Information of Report at https://www.absolutereports.com/drug-addiction-pipeline-review-h1-2018-11651732
Top Players in Drug Addiction market report are Addex Therapeutics Ltd, Aelis Farma SAS, Aphios Corp, BioCorRx Inc, Charleston Laboratories Inc, Chiesi Farmaceutici SpA, Consegna Pharma Inc, Curemark LLC, Egalet Corp, Embera NeuroTherapeutics Inc, F. Hoffmann-La Roche Ltd, Heptares Therapeutics Ltd, Immunovaccine Inc, InterveXion Therapeutics LLC, Intra-Cellular Therapies Inc, Johnson & Johnson, Kyorin Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, Omeros Corp, Orexigen Therapeutics Inc, P2D Bioscience, Saniona AB, Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd, Vectura Group Plc.
The Scope of Drug Addiction Market Report: Drug Addiction Market Pipeline guide provides a snapshot of the global therapeutic landscape by companies and universities/research institutes based on information derived from company and industry-specific sources. It covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. Drug Addiction Market pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities, as well as The pipeline guide, evaluates Drug Addiction Drug Addiction therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
Request for Sample PDF at https://www.absolutereports.com/enquiry/request-sample/11651732
Reason to Buy Drug Addiction Market Report-
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies, identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage, Identify and understand important and diverse types of therapeutics under development for Drug Addiction Market, Identify potential new clients or partners in the target demographic, Develop strategic initiatives by understanding the focus areas of leading companies , Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics, Devise corrective measures for pipeline projects by understanding Drug Addiction Market pipeline depth and focus of Indication therapeutics, Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope, Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
BIGGGG BUYYYYYY !!!!
WOW !!! 5.5 million shares for $0.20/ share total of 1.1 million US dollars in one private placement transaction .... THAT IS HUGE !!!!!
That is DOUBLE the Current share market value
BioCorRx Raises $1.1 Million at Premium to Market
7:00 AM ET 6/6/18 | GlobeNewswire
BioCorRx Raises $1.1 Million at Premium to Market
ANAHEIM, CA, June 06, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced the Company recently sold 5.5 million shares of common stock in a private placement at a price of $0.20 per share for proceeds of $1.1 million. The $0.20 price paid by both new and existing investors represents a premium to the current market price. Investors also received 100% warrant coverage with the warrants having a three-year term and an exercise price of $1.00 per share. This capital is enabling BioCorRx to continue to work towards FDA approval of BICX102, the Company's naltrexone implant for the treatment of opioid and alcohol use disorders.
Brady Granier, President, CEO and Director, stated, "We are pleased to announce that our investors continue to support the management team at BioCorRx and the future growth and success of the Company. We are fortunate to have attracted a dedicated group of investors who believes in management and a product that we feel may have a significant impact on the current opioid crisis as well as alcohol use disorder. This is a testament to the hard work of our team. With this latest investment, work on BICX102 continues while we also wait for the outcome of our recent NIH/NIDA grant application for BICX102. We look forward to getting BICX102 approved to fight these substance use disorders."
Lourdes Felix, CFO, COO and Director, stated, "This investment constitutes a vote of confidence in our future, an affirmation of the work we have done to build our business and, most important, a validation of the tremendous opportunities we see ahead. As we execute on our plan, we look forward to driving significant value for all of our shareholders."
Additional Information
The securities issued and sold in the private placement were sold pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of the use of sustained release naltrexone, usually in implantable form and under the direction and care of an independent licensed physician. Implant forms of naltrexone deliver the non-addictive medicine which is an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, as well as some of their effects. The second component of the program developed by BioCorRx Inc. is a proprietary cognitive behavioral therapy (CBT) program specifically tailored for the treatment of alcohol and opioid use disorders for those receiving sustain release naltrexone treatment. The behavioral portion of the program also includes overlapping peer recovery support and tracking. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
nrudman@crescendo-ir.com
> Dow Jones Newswires
VERY Promising !!!!!
BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102
7:30 AM ET 5/22/18 | GlobeNewswire
BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102
ANAHEIM, CA, May 22, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it has submitted a grant application to the National Institutes of Health (NIH) to fund the development and study plans for BICX102, the Company's sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. This specific grant opportunity, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3), was created as a result of the current opioid epidemic.
Brady Granier, President, CEO and Director, stated, "The NIH provides support for the research and development of new treatments that can help address the current epidemic of opioid use disorder, which is estimated to affect over 2 million Americans. We are seeking funding from the NIH that could potentially cover the entire cost of the BICX102 development plan. We believe that this new grant opportunity is well suited for our product, as BICX102 addresses an unmet need in the treatment of opioid use disorder of an FDA approved, single administration, multi-month opioid antagonist treatment. While waiting for the outcome of this very comprehensive grant submission, we have already started procuring equipment and supplies needed for the manufacturing portion of the development plan."
BioCorRx Provides Business Update for the First Quarter of 2018
7:30 AM ET 5/21/18 | GlobeNewswire
BioCorRx Provides Business Update for the First Quarter of 2018
ANAHEIM, CA, May 21, 2018 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the first quarter ended March 31, 2018.
First Quarter 2018 Business Highlights
-- In January, BioCorRx(R) retained regulatory drug experts Priya Jambhekar
and Bruce Firestone to assist in drug development and regulatory process
for the Company's product pipeline.
-- In January, BioCorRx(R), in collaboration with One Day at a Time Program
(ODAAT), announced a pilot for the BioCorRx(R) Recovery Program in
Philadelphia, Pennsylvania.
-- In February, the Company announced that the U.S. Food and Drug
Administration (FDA) deemed the 505(b)(2) pathway as an acceptable route
for approval for BICX102, a sustained release naltrexone implant for the
treatment of opioid and alcohol use disorders; the Company plans to apply
for dual indications, both opioid use disorder and alcohol use disorder,
within the same application.
-- In March, BioCorRx(R) reported it successfully enrolled twelve
individuals to date in the new weight management pilot program, and the
initial results have been positive, as reported by patients.
Brady Granier, CEO, President, and Director of BioCorRx, Inc., stated, "We made significant headway in the first quarter of 2018. In January, we held a pre-IND meeting with the FDA for BICX102 with the National Institute on Drug Abuse (NIDA) in attendance. The FDA has deemed the 505(b)(2) pathway as acceptable for BICX102, which should result in less studies, lower costs, and an abbreviated path to approval. The possibility of getting approval on both opioid and alcohol use disorders simultaneously should also provide an enormous time and cost savings to us. We are also seeking grant assistance from the National Institutes of Health (NIH) for BICX102."
"In the first quarter, we announced a pilot for the BioCorRx(R) Recovery Program in collaboration with ODAAT, a program funded by the city of Philadelphia and state of Pennsylvania. This will be a paid demonstration pilot in which the BioCorRx Recovery Program will be used to treat several individuals suffering from opioid and alcohol use disorders. The ODAAT program assists over 56,000 residents of Philadelphia. We continue to gain momentum with the BioCorRx(R) Recovery Program as independent treatment providers across the country report successful results using our program to treat their patients."
Lourdes Felix, CFO, COO and Director, commented, "We continue to be very prudent in managing our expenses, while seeking to increase opportunities for non-dilutive funding such as the NIH grant we are pursuing. At the same time, we are also exploring strategic partnerships that could help accelerate our commercial activities. Overall, we believe we are on track for FDA approval of BICX102 in an abbreviated pathway. At the same time, we continue to advance our BioCorRx Recovery Program, through a low-cost and highly scalable partnering strategy with clinics across the U.S. According to the Substance Abuse and Mental Health Services Administration's (SAMHSA's) National Survey on Drug Use and Health there are over 23 million Americans addicted to drugs and alcohol with few viable options. Not only is this a large and underserved market, but we believe that both BICX102, as well as our BioCorRx Recovery Program, offer these patients real hope for a brighter future."
About BioCorRx
BioCorRx, Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx, Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx, Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
> Dow Jones Newswires
BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant
7:00 AM ET 4/30/18 | GlobeNewswire
BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant
ANAHEIM, CA, April 30, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today reported that Dr. Mark Siegel, commented on the advantages of sustained release naltrexone implants in treating addiction on Varney & Co. on Fox Business. The interview follows a similar report on Fox Business with actor Jeremy Miller, best known for his role as Ben Seaver on the hit TV show Growing Pains, in which Mr. Miller discussed how BioCorRx's sustained release naltrexone has changed his life.
In the interview, Dr. Siegel commented on excitement around the concept of an implant that gradually releases the treatment. He further noted that the future of treating addiction will include products such as a sustained release naltrexone implant, which goes right to the source of the problem -- addiction centers in the brain. As previously reported, BioCorRx is pursuing FDA marketing clearance for its sustained release naltrexone implant, BICX102.
The segment can be viewed online at http://video.foxbusiness.com/v/5777300197001/?#sp=show-clips.
Dr. Marc Siegel, a practicing internist, joined FOX News Channel (FNC) as a contributor in 2008. In addition to his role at FNC, Dr. Siegel serves as an associate professor of medicine at NYU Langone Medical Center and as the Medical Director of Doctor Radio with NYU Langone and SiriusXM Satellite Radio.
Varney & Co. is a daily morning news/talk program hosted by British-American economic and political commentator Stuart Varney on Fox Business on weekdays 9 AM - 12 PM ET. The show includes market coverage, current events coverage, and interviews and commentary with Wall Street experts.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
> Dow Jones Newswires
April 30, 2018 07:00 ET (11:00 GMT)
BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company's Sustained Release Naltrexone Implant for Alcohol Use Disorder
April 26, 2018 08:47 ET | Source: BioCorRx Inc
ANAHEIM, CA, April 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, as well as actor Jeremy Miller, best known for his role as Ben Seaver on the hit TV show Growing Pains, appeared as guests on Varney & Co on Fox Business.
Mr. Miller discussed his personal experience with alcoholism and how the implant has been “an absolute game changer” after trying other treatments, unsuccessfully. In discussing the implant, he noted, “Within hours I started noticing the effects, and what you notice is what’s not there – that constant obsessive need, it just kind of vanished. It’s like a light switch turned off for me.”
During the interview, Mr. Granier discussed the advantages of the Company’s sustained release naltrexone implant, including its efficacy, price points and recent meeting with the FDA regarding its plans to submit the implant, named BICX102, for marketing clearance in order to gain wider payor acceptance.
The segment can be viewed online at http://www.foxbusiness.com/shows/varney-co.html.
Varney & Co. is a daily morning news/talk program hosted by British-American economic and political commentator Stuart Varney on Fox Business on weekdays 9 AM - 12 PM ET. The show includes market coverage, current events coverage, and interviews and commentary with Wall Street experts.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
2 minutes of trading with 214k shares traded already !! Mmmmmm
BioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource Fair
7:18 AM ET 4/13/18 | GlobeNewswire
BioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource Fair
ANAHEIM, CA, April 13, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company), a developer and provider of advanced solutions in the treatment of alcohol and opioid addition, today announced that the Company will participate in the first annual Orange County Recovery Collaborative (OCRC) resource fair on Saturday, April 14th.
BioCorRx is a member of OCRC, which is designed to eliminate barriers and connect resources to those suffering from substance abuse. The resource fair will address prevention, education, resources, and services. There will be booths, guest speakers, workshops, and education sessions throughout the day. Assessments will be available for those seeking services.
Brady Granier, CEO, President, and Director, stated, "We are very proud be a member of OCRC and to support its important mission in the community. This is an important event for Orange County as it's the first of its kind with many agencies coming together for one common purpose, which is to combat addiction. We encourage anyone who is suffering or has a loved one suffering from addiction to stop by for this free resource fair."
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
> Dow Jones Newswires
April 13, 2018 07:18 ET (11:18 GMT)
BioCorRx to Exhibit at ASAM 49th Annual Conference in San Diego, California
7:30 AM ET 4/10/18 | GlobeNewswire
BioCorRx to Exhibit at ASAM 49th Annual Conference in San Diego, California
ANAHEIM, CA, April 10, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company), a developer and provider of advanced solution in the treatment of alcohol and opioid addition, today announced that the Company will have a tabletop exhibit at the American Society of Addiction Medicine (ASAM) 49th Annual Conference on April 12th through the 15th, in San Diego, California. ASAM is the leading addiction medicine professional society in the U.S. representing over 4,300 physicians, clinicians and professionals with a focus on addiction and its treatment.
The ASAM Addiction Medicine conference is widely recognized as the essential primer for physicians and other healthcare professionals who are preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients who medical problems are cause or exacerbated by substance use disorders.
Brady Granier, CEO, President, and Director, stated, "We are looking forward to attending ASAM's 49th Annual Conference this week. Physicians, healthcare professionals and primary care providers are continuing to look for the latest and most innovated ways to help their patients that suffer from substance abuse. The BioCorRx(R) Recovery Program is an ideal match for primary care physicians who are entering the field of addiction medicine. This program enables these professionals to treat patients in their office with medicine like naltrexone, while providing outpatient behavioral therapy through our turnkey program. The event will also give us the opportunity to talk to many of the top addiction medicine providers about BICX102, our naltrexone implant for which we are seeking FDA approval."
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
> Dow Jones Newswires
April 10, 2018 07:30 ET (11:30 GMT)
"FOX BUSINESS" VIDEO TODAY 4/9/18 !!!
Sam Moore on overcoming addiction
Apr. 09, 2018 - 5:14 - Legendary soul man Sam Moore and BioCorRx CEO Brady Granier on the company's implanted device that helps combat opioid addiction.
http://video.foxbusiness.com/v/5766909305001/?#sp=show-clips
BioCorRx Partner, Virtual Reality Medical Center, Submits Small Business Innovation Grant Application to the National Institute of Health
7:30 AM ET 4/5/18 | GlobeNewswire
BioCorRx Partner, Virtual Reality Medical Center, Submits Small Business Innovation Grant Application to the National Institute of Health
ANAHEIM, CA, April 05, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that its partner, Virtual Reality Medical Center (VRMC), has submitted a Small Business Innovation Research (SBIR) grant application to the National Institute of Health. As previously announced last year, BioCorRx partnered with VRMC to conduct a study on the BioCorRx Recovery Program and one of the Company's long-lasting naltrexone implants.
VRMC has over 30 years of experience in applying for and securing government grants and contracts. If approved, the grant will be used to conduct studies on the naltrexone implant and cognitive behavioral therapy (CBT) recovery program and its effect on alcohol use disorder in a virtual reality setting.
A recent CDC study shows that excessive alcohol use in the U.S. kills about 88,000 people each year and is a major drain on the American economy. The cost of excessive alcohol use in the United States reached $249 billion in 2010 and approximately 77% of these costs were due to binge drinking.
Brady Granier, President, CEO and Director, stated, "Our company started out treating alcohol use disorder before the opioid epidemic rightfully gained widespread notoriety. It's important to note that alcohol use disorder (AUD) is a perpetual, massive problem that oftentimes doesn't get the attention it deserves. Although alcohol is legal and socially acceptable, AUD is also a major national crisis that we must not ignore. VRMC is very experienced in submitting grant applications and running clinical studies. They plan to conduct a study on our naltrexone implant and how it affects the cravings of people with AUD through various virtual reality settings. We believe that by conducting this study, we will gain more third-party support for our program, which has already helped countless individuals over the years. Not only can this study potentially be helpful for educating medical practitioners, but it may also help lay the foundation for broader national awareness and reimbursement. It's also worth noting that this application by VRMC is separate from the grant application that is currently being finalized for submission to the National Institute on Drug Abuse (NIDA)."
Dr. Mark D. Wiederhold, M.D., Ph.D, CEO of VRMC, commented, "We look forward to hearing the response from National Institute of Health, which should come in the second half of the year. We truly believe in the effectiveness of the naltrexone implant combined with BioCorRx's CBT recovery program. Our mission is to combine both pharmacological and technical interventions which we believe represents the future of successfully addressing addiction."
About VRMC
VRMC brings over 20 years of experience in the use of advanced technologies, such as Virtual Reality (VR), tele-behavioral health and real-time biosensor data analysis using artificial intelligence. VRMC has been effectively treating patients in its clinics and providing comprehensive VR training and treatment programs to the U.S. Government, the Department of Defense, the Veterans Administration, NATO and European Commission. VRMC is a leader in providing the tools for patient assessment and treatment both in the clinic and is actively transitioning healthcare to both mobile devices and the home setting.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com